4.6 Article

Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure

Related references

Note: Only part of the references are listed.
Review Pharmacology & Pharmacy

An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases

Si Chen et al.

Summary: This review focuses on recent research advances on different PDE isoforms in the heart, discussing their expression patterns and biological functions. Current limitations and future directions in research are also addressed, along with the development of PDE inhibitors.

EXPERT OPINION ON DRUG DISCOVERY (2021)

Review Cell Biology

The Role of Cyclic AMP Signaling in Cardiac Fibrosis

Marion Delaunay et al.

CELLS (2020)

Article Multidisciplinary Sciences

Cells of the adult human heart

Monika Litvinukova et al.

NATURE (2020)

Review Cardiac & Cardiovascular Systems

cGMP manipulation in cardiometabolic disease: chances and challenges

Jens Jordan et al.

CURRENT OPINION IN CARDIOLOGY (2019)

Review Cardiac & Cardiovascular Systems

cAMP/PKA signaling compartmentalization in cardiomyocytes: Lessons from FRET-based biosensors

Alessandra Ghigo et al.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)

Review Physiology

Visualizing Cyclic Adenosine Monophosphate in Cardiac Microdomains Involved in Ion Homeostasis

Vladimir Dikolayev et al.

FRONTIERS IN PHYSIOLOGY (2019)

Review Cardiac & Cardiovascular Systems

Functions of PDE3 Isoforms in Cardiac Muscle

Matthew Movsesian et al.

JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2018)

Article Multidisciplinary Sciences

Generation and phenotypic characterization of Pde1a mutant mice

Xiaofang Wang et al.

PLOS ONE (2017)

Article Pharmacology & Pharmacy

Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats

Morten Laursen et al.

BRITISH JOURNAL OF PHARMACOLOGY (2017)

Article Cardiac & Cardiovascular Systems

Ca2+/calmodulin-activated phosphodiesterase 1A is highly expressed in rabbit cardiac sinoatrial nodal cells and regulates pacemaker function

Yevgeniya O. Lukyanenko et al.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2016)

Review Pharmacology & Pharmacy

Novel approaches to targeting PDE3 in cardiovascular disease

Matthew Movsesian

PHARMACOLOGY & THERAPEUTICS (2016)

Article Multidisciplinary Sciences

PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction

Walter E. Knight et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Article Pharmacology & Pharmacy

PDE1 isozymes, key regulators of pathological vascular remodeling

Stefan Chan et al.

CURRENT OPINION IN PHARMACOLOGY (2011)

Article Biochemistry & Molecular Biology

Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes

Fabrice Vandeput et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2007)

Article Physiology

Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1

Fiona Murray et al.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2007)

Article Multidisciplinary Sciences

A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis

B Ding et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)